

## ADACOLUMN, A GRANULOCYTE AND MONOCYTE / MACROPHAGE ADSORPTION APHERESIS DEVICE

Condition of storage: 1 to 30°C

Sterilization: Steam sterilization at high vapor pressure

### 1. Content

Adacolumn contains 220 g of cellulose acetate beads bathed in physiological saline as the column adsorptive carriers.

### 2. Indications

2.1 Inducing remission in patients with inflammatory bowel disease (active ulcerative colitis and Crohn disease).

2.2 Suppressing subjective and objective symptoms in patients with rheumatoid arthritis in the inflammatory stage whose symptoms might be resistant to standard drug therapy.

2.3 Treatment of patients with ocular Behçet disease.

2.4 Treatment of patients with systemic lupus erythematosus (SLE).

### 3. Contraindications

Adacolumn must not be used in patients with a peripheral circulation count of less than 2.000 granulocytes per micro liter.

In patients with a granulocyte count below this limit, due to the pharmacological pre-treatment, Adacolumn can be used, if the granulocyte count is greater than 1.000/ $\mu$ L, under close monitoring. Studies in patients with SLE and comparable granulocyte count did not show further decrease under the Adacolumn treatment.

### 4. Warning

4.1 Caution should be taken with patients suffering from or suspected of concomitant infections, as apheresis treatment may exacerbate symptoms.

4.2 Caution should be taken with patients who have a history of hypersensitivity to heparin (anticoagulant).

4.3 Caution should be taken with patients who have a low red blood cell count (RBC counts, under  $300 \times 10^9/\text{mm}^3$ ), severe dehydration (RBC counts, over  $600 \times 10^9/\text{mm}^3$ ), hypercoagulable blood (fibrinogen over 700 mg/dL). Apheresis treatment should not be initiated until these conditions have normalized.

4.4 In patients who are receiving angiotensin converting inhibitors, blood pressure and heart rate should be closely monitored.

4.5 In patients with hepatic or renal failure, usefulness or harmfulness of Adacolumn treatment must be carefully assessed by the patient's physician.

4.6 Adacolumn treatment has not been fully investigated in elderly patients.

4.7 In patients with severe cardiovascular disease, usefulness or harmfulness of Adacolumn treatment must be carefully assessed by the patient's physician.

4.8 In patients with fever (body temperature over 38°C; suspected infection) there may be an increased possibility of side effects associated with Adacolumn treatment.

4.9 In pregnant and lactating women the safety of Adacolumn treatment has not been investigated; therefore, Adacolumn should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. In lactating women, a decision should be made on whether or not to discontinue nursing while undergoing Adacolumn treatment.

4.10 Adacolumn treatment has not been fully investigated in pediatric patients.

4.11 Patient's vital signs should be continuously monitored during apheresis treatment. If any abnormality is observed, the apheresis should be stopped and a physician called.

4.12 If a central venous catheter is to be used, be aware of the general complications associated with such a method, such as activation of the coagulation system, formation of emboli, pulmonary embolism, and clogging of catheter.

### 5. Data on Adverse Reactions

Adverse events reported in Japan.

Out of 367 patients (286 UC and RA patients who participated in clinical trial and 81 patients involved in post marketing surveillance), adverse events including abnormal values in clinical parameters were observed in 39 cases (10,6%).

#### Adverse reactions

Frequency Type	>5%	0,1% to $\leq$ 5%
Circulatory organ	–	Hypotension, palpitation, flush
Other symptoms	–	Fatigue, malaise, headache, vertigo, nausea, fever, chest pain, stagger
Frequency of abnormal test values	$\alpha_1$ -, $\alpha_2$ - and $\beta$ -globulin (out of 59 cases)	GOT, GPT, Cholesterol, urine protein, BUN (blood urea nitrogen), K, Na, Cl, Ca, total protein, albumin, Albumin/Globulin ratio, ALP, LDH, $\gamma$ -GTP, $\gamma$ -globulin

In addition to the adverse events described in the above table, adverse events commonly seen in extracorporeal circulation, such as vomiting, elevation of blood pressure, haemolysis, haematuria, coughing, abdominal pain, and lumbar pain, were reported. Allergic reactions (rash, angioedema (Quincke edema)) are possible. (If abnormal reactions occur, the apheresis should be discontinued and appropriate corrective measures taken.)

Adverse events reported outside Japan  
In pilot studies in Sweden (10 cases), United Kingdom (22 cases), Australia (27 cases), and Italy (15 cases), the following adverse events were reported with frequency of above 5%: anxiety, anaemia, systemic pain, abdominal pain, insomnia, and viral infections.

### 6. Essential Information for Adacolumn treatment

#### 6.1 Apheresis time and flow rate

Adacolumn system should be operated at a flow rate of 30 mL/min, duration of one apheresis treatment is 60 min. The investigated course of treatment is one apheresis per week for a period of 5 consecutive weeks.

#### 6.2 Disposable products

Adacolumn and circuit are for single use only (disposable).

#### 6.3 Handling of Adacolumn

Adacolumn should only be used in an appropriate clinical setting.

6.4 It is necessary for the operator to carefully study the instruction for use before using Adacolumn system. The medical staff must be given/shall have adequate training for operating the system.

6.5 Blood inflow and outflow should be established in suitable veins. There is no need for establishing a shunt or port system.

6.6 Adacolumn should be used under the supervision of a physician who has been fully versed in the condition of the patient.

6.7 Before Adacolumn treatment is initiated, the physician must evaluate the need and usefulness of the column against the risk of adverse reactions. If serious reactions occur, the apheresis should be discontinued and appropriate corrective measures taken.

6.8 Patients being treated with Adacolumn should be monitored. In particular, their vital signs (body temperature, blood pressure, pulse rate, respiration rate), blood coagulation time, WBC counts should be monitored. If abnormalities are observed during the treatment, the apheresis should be stopped and/or other appropriate actions taken.

### 7. Prior to starting the Apheresis treatment

#### 7.1 Preparations

1) The package and the covering plastic sheet must be checked for signs of damage. Possible damage to the package of the circuits and needles should also be checked before use. If the packages for the Adacolumn, Adacircuit, or needles, are damaged, they should not be used.  
2) Adacolumn should not be used past the expiry date.  
3) Adacolumn should be removed from the plastic bag just before priming.

4) Care should be taken to avoid contamination when blood circuit lines are connected to Adacolumn.

5) The priming procedures should be carried out according to the operating procedures detailed in 7.3.

6) Foam or bubbles in the Adacolumn or the circuit lines can trigger blood coagulation. Therefore, they must be free from air bubbles and foams prior to apheresis.

7) If a leak is discovered during priming in the column or the circuit lines, the leaky component should be discarded.  
8) Priming should be performed sufficiently, until the filling solution within the Adacolumn and circuit is fully replaced with fresh physiological saline.

9) To avoid contamination of components, Adacolumn and circuit should be used as soon as priming has been completed.

10) Adacolumn and circuit should not be left unused after being removed from the sterilized bag or after priming.

11) Caution should be taken to avoid contaminating blood during the apheresis or blood retrieving operation.

#### 7.2 Necessary components

- 1 Adacolumn
- 1 Bag containing 1 L sterile saline
- 2 Bags containing 0,5 L sterile saline
- 1 Bag containing 1 L sterile heparinized saline (4.000 I.U.)
- 1 Blood pump (Adamonitor)
- 1 Set of tubings (Adacircuit)
- 1 Infusion pump for the heparin application
- 1 Column holder (Adastand)
- Forceps (as necessary)
- Heparin (as necessary)
- 2 Needles (e.g. 18G)
- 1 Waste bag
- Waste containers for priming saline, sharps, blood, etc.

Caution: The instruction manual of the relevant components should be read carefully.

#### 7.3 Preparation

##### 7.3.1 Priming the apheresis unit

- 1) Suspend the 1 L saline bag on the stand.
- 2) Close clamp 1 of the blood inflow line and connect the blood inflow line with the saline bag.
- 3) Insert the pump tube into the pump and the pillow sensor into the pillow sensor unit (Fig. 1).

##### 7.3.2 Preparation of the blood outflow system

- 1) Connect the venous pressure monitor line with the venous pressure monitor (pressure monitor port).
- 2) Connect the end of the blood outflow line with the waste bag and suspend the bag on the stand.

##### 7.3.3 Filling of the blood inflow line system

- 1) Open clamp 1 of the blood inflow line and the roller clamp of the extra infusion line. Fill the blood inflow line, the heparin infusion line, and the extra infusion line with saline. Fill the drip chamber of the extra infusion line up to approximately 90% and close the roller clamp. Connect the infusion line with the 0,5 L saline bag. Suspend this bag on to the stand.
- 2) Start the pump and fill air-free the remaining part of the blood inflow line.
- 3) Please note: Direct the saline into the waste container and avoid contact with the waste container by using the holder.
- 4) Stop the pump.




Fig.1

### 7.3.4 Connection of Adacolumn

- 1) Remove Adacolumn from the package and fit it to column holder on the stand.
  - 2) Remove the cap from the red-colored end of Adacolumn and connect the blood inflow line firmly to the Adacolumn. Place Adacolumn into the column holder the way that the red connection is facing downward. Remove the cap on the blue-colored exit of Adacolumn and connect the blood outflow line (Fig. 2).
- Please note: The direction of flow is from the lower end of the column towards the upper end, as indicated by the arrow on the column.

### 7.3.5 Washing of the Adacolumn and circuit

- 1) Let about 1 L saline run through Adacolumn and circuit at a flow rate of 100 mL/min by starting the pump. Remove the air from the column by shaking and rotating Adacolumn.
- 2) Fill the air trap chamber with saline up to a level of about 80% by opening clamp 3 and the cap at the end of this line. When the drip chamber is filled up to 80%, close clamp 3.
- 3) After the saline is nearly exhausted, stop the pump. Replace the empty saline bag by the bag with the 1 L heparinized saline. Start the pump at a flow rate of 100 mL/min.

Running the pump will replace the standard saline in the column and the flow lines with heparinized saline. Occasionally rotate and shake the column to ensure adequate priming of the column with heparinized saline and complete elimination of the air from Adacolumn and Adacircuit.

Please note:

- Ensure that all the priming heparin saline flows into the waste bag.
  - Make sure that the heparin infusion line is also primed with heparinized saline by opening the cap of this line.
  - Ensure that all air bubbles are eliminated from the column and the whole tube system when following chapter 7.3.5.
  - If necessary, adjust the liquid surface by filling the air trap (drip chamber) to approx. 80% as described in chapter 7.3.5.
- 4) Insert the blood outflow line into the air sensor and into the clammer.
  - 5) After most of the heparinized saline has been dispensed, stop the pump and close clamps 1 and 2.




Fig. 2

### 7.4 Leakage test

- 1) Set the upper limit of the venous pressure to 240 mmHg as described in the manual of the monitor or pump. Close clamp 2 at the end of the blood outflow line.
- 2) Run the pump with a flow rate of 30 mL/min until a venous pressure of approximately 200 mmHg has been reached. Stop the pump.
- 3) Check, if the venous pressure level remains steady close to 200 mmHg and there is no leakage in the system.
- 4) Open clamp 2 of the blood outflow line clamp and as a consequence the venous pressure should decrease.
- 5) Close clamp 1 of the blood inflow line and clamp 2 of the blood outflow line.

### 7.5 Procedures for the apheresis

- 1) A venous access to a vein of the right and the left arm should be established by a physician or a well-trained nurse under observation by a physician, using a 18G needles (or a similar adaptation).
- 2) Connect the blood inflow line and the blood outflow line to the venous access established above (Fig. 3). Alternatively, it is possible to connect the blood outflow line to the venous access only when the blood reaches the end of the blood outflow line.




Fig.3

- 3) Make sure that clamps 1 and 2 are open and start running the pump at a flow rate of 30 mL/min for 60 min. Adjust the upper and lower limit of the venous pressure monitor as close as possible to the actual working pressure during the apheresis.
- 4) Subsequently a continuous heparin infusion should be started via the heparin infusion line. Also, bolus dose of heparin can be given.

The amount of anticoagulant necessary may vary according to patients' condition (weight, disease, sensitivity to anticoagulant, etc.). The attending physician should assess what is the appropriate dosage. If any abnormalities, caused by excessive or insufficient volume of anticoagulant, are observed during the apheresis, appropriate measures should be taken immediately.

Please note:

- Patients should be observed for the duration of the treatment. If an abnormality is observed, the treatment should be stopped or the flow rate reduced under the guidance of the responsible physician.
- Flow rate and the pressure of the blood inflow line and venous pressure should be monitored for the duration of treatment, as indicated by the fault detection system of the Adamonitor (optical and acoustical alarm).

- In the case that there are access problems the extra infusion line facilitates an infusion of without the necessity of interrupting the apheresis.

### 7.6 Procedures for returning residual blood after apheresis

- 1) Stop the blood pump after termination of the apheresis time.
- 2) Close the clamp on the blood inflow line (clamp 1), remove the inflow line from the patient and connect it to a bag containing 500 mL saline. Invert the column, so that the red-colored end is facing upward.
- 3) Open clamp 1 and then run the pump at the flow rate of 30 mL/min. Re-transfuse the extracorporeal blood by replacing the blood with saline.
- 4) When the blood in Adacolumn has been replaced by saline, stop the pump. Close clamp on the blood outflow line (clamp 2) and remove this line from the patient.
- 5) Be careful of personal contamination when disconnecting the circuit and the column.

Caution: Ensure that the blood outflow line is removed from the patient before disconnecting the flow lines from Adamonitor.

### 8. Conditions of storage and transport

The storage conditions for Adacolumn are clearly indicated on the product package. The column should be protected from direct sunlight, heat, and not stored in places where the temperature is likely to fall to freezing point or lower. The storage temperature is 1 to 30°C. During transport, the package must not be subjected to trauma, violent vibrations or shock.

### 9. Warranty and Liability

Japan Immunoresearch Laboratories Co., Ltd. warrants Adacolumn is manufactured in accordance with their specifications and in compliance with good manufacturing practices, ISO 13485, applicable industry standards, and regulatory requirements. In the event that a unit is found to be defective (damaged or is malfunctioning) due to manufacturing or packaging processes, the unit will be replaced at no extra cost.

The manufacturer does not accept responsibility for personal or material damage as a result of misuse of this product.

The company (JIMRO, Japan Immunoresearch Laboratories Co., Ltd.) is not liable for any damage arising from the reuse of the single-use disposable Adacolumn or for use in indications other than those recommended for Adacolumn.

### 10. Manufacturer

Japan Immunoresearch Laboratories Co., Ltd.  
351-1 Nishiyokote-machi, Takasaki-shi, Gunma  
370-0021, Japan.

### Authorized Representative

Otsuka Pharmaceutical Europe Ltd.  
Commonwealth House, 2 Chalkhill Road, Hammersmith,  
London, W6 8DW, United Kingdom  
Phone: +44 -20- 8600- 6770  
Fax: +44-20-8600-6794

11. If an adverse event (accidents and other incidents and near-accidents) should occur this should as soon as possible be reported to Otsuka Pharmaceutical Europe Ltd.

Date written: 24 June 2004